Authors: Sutep Jaruratanasirikul Somchai Sriwiriyajan
Publish Date: 2007/03/07
Volume: 63, Issue: 5, Pages: 451-456
Abstract
Our study was conducted in 12 healthy volunteers in two phases In phase 1 from days 1–28 all subjects were randomly assigned to a twoway crossover study of a nevirapine regimen nevirapine 200 mg once daily for 7 days and an itraconazole regimen itraconazole 200 mg once daily for 7 days with a 14day washout period between Phase 2 from days 43–49 was performed 14 days after phase 1 ended and all subjects received a combination regimen nevirapine 200 mg combined with itraconazole 200 mg once daily for 7 days Nevirapine pharmacokinetic studies were carried out starting with the seventh dose of nevirapine in the nevirapine regimen on days 7–10 or 28–31 and the combination regimen on days 49–52 Itraconazole pharmacokinetic studies were carried out starting with the seventh dose of itraconazole in the itraconazole regimen on days 7–10 or 28–31 and the combination regimen on days 49–52There was no significant difference in nevirapine pharmacokinetic parameters between the nevirapine and combination regimens Itraconazole plasma concentrations were lower when it was administered in the combination regimen than when it was administered in the itraconazole regimen The mean Cmax AUC0–96 and t 1/2 of itraconazole were significantly reduced by 38 61 and 31 respectively
Keywords: